Lumenis OptiLIGHT is the first and only Intense Pulsed Light (IPL) device FDA-approved for management of dry eye disease due to Meibomian Gland Dysfunction (MGD) - the most common cause of evaporative dry eye.

OptiLIGHT delivers precise pulses of broad-spectrum light to the periorbital area (cheeks and nose), targeting multiple underlying causes of dry eye diseases:

• Reduces inflammation by coagulating abnormal telangiectatic blood vessels that contribute to chronic ocular surface inflammation

• Improves meibomian gland function by decreasing gland obstruction and allowing better lipid secretion

• Reduces microbial and parasitic load, including Demodex mites and bacteria that exacerbate eyelid margin disease

• Enhances tear film stability, reducing tear evaporation and increasing ocular surface comfort

The treatment also promotes photobiomodulation (PBM), which supports tissue repair and anti-inflammatory effects on a cellular level.